CTIS2024-512097-98-00招募中1 期
An open-label dose escalation study to evaluate safety, tolerability, biodistribution and efficacy of [90Y]Y-PentixaTher for the therapy of recurrent or refractory primary or isolated secondary central nervous system lymphoma - PTT101
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed informed consent, by the patient or an authorized legal guardian in case the patient is temporarily not competent due to his or her disease, obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study., For male patient whose partner is of child-bearing potential: patient is willing to ensure that he and his partner use effective contraception during the study and for six months after 90Y-PTT treatment., ECOG performance status = 2., Confirmed presence of CXCR4 on technically evaluable tumor lesions documented by a visually CXCR4-positive [68Ga]Ga-PentixaFor PET scan within two months prior to enrolment in the study or during Screening., Blood test results as follows: a. Absolute neutrophil count: > 1.0 x 10^9 /L b. Hemoglobin: = 8 g/dL c. Platelets: = 75 x 10^9/L d. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP): = 3 x ULN (upper limit of normal) e. Serum creatinine: = 2 x ULN and Cockroft Gault calculated glomerular filtration rate (GFR) = 50 mL/min f. Bilirubin: = 3 x ULN., Patients of either gender aged > 18 years., Body weight = 180 kg., At least one measurable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the brain parenchyma or measurable meningeal lesion., Histologically, cytologically or radiologically confirmed relapsed/refractory PCNSL or relapsed/refractory SCNSL. Initial histologic confirmation at first diagnosis is mandatory. No peripheral lymphoma evidence is allowed., Recurrent or refractory CNSL a) For recurrent disease, comprising new lesions or recurrent CNSL after a CR at that site, there are no maximum number of recurrences. b) Refractory CNSL comprises patients with non-responding CNSL to frontline therapy, or progressive disease after an initial,partial response (PR)., Stored stem cells with at least = 2 x 10^6 CD34+ cells/kg of body weight., If sexually active female patient of childbearing potential: patient agrees to take adequate contraceptive measures during study participation and agrees to continue use of this method for the duration of the study and for six months after the last dose., Female patient without childbearing potential: documented history (e.g., tubal ligation or hysterectomy) or is post-menopausal.
排除标准
- •Known or suspected hypersensitivity to study product(s) or related products., Presence of active infection, or history of serious infection six weeks prior to IMP administration. Patients with uncontrolled human immunodeficiency virus (HIV) infection as well as acute or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are excluded (Note: Patients on antiretroviral therapy (ART) with controlled HIV infection (defined as sufficient ART compliance, non-measurable HIV and CD4+ T helper cells > 200/microL) may be enrolled, if considered eligible for study treatment by the investigator.)., SCNSL with systemic involvement., Brain radiation therapy = 180 days before IMP infusion., Chronic use (> 21 days) of immunosuppressive drugs, e.g., steroids for systemic autoimmune disease, due to previous organ transplantation, or other clinically evident form of immunodeficiency. Patients receiving only acute treatment (less than 21 days) with corticosteroids can be included., Any mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study, and/or evidence of an uncooperative attitude without designated legal representative., Contraindication for contrast-enhanced MRI as set out in the relevant institutional guidelines (e.g., pacemaker, defibrillator, aneurysm clip, metal in the body, renal insufficiency, severe claustrophobia etc.) or contraindication for the use of gadolinium contrast for MRI., Previous participation in this study. Participation is defined as signed informed consent., Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). A pregnancy test will be performed at the start of the study for all female patients of childbearing potential (i.e., not surgically sterile or two years postmenopausal)., Male of reproductive age who or whose partner(s) is not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)., Participation in any clinical study of an approved or non-approved IMP within the last 30 days (or = 5 terminal elimination half-lives of previous IMP, whichever is longer) before screening., Any disorder (e.g., active infection, unstable angina pectoris, cardiac arrhythmia (excluding atrial fibrillation and atrial flutter, uncontrolled congestive heart failure), poorly controlled hypertension, poorly controlled diabetes mellitus [HbA1c = 9%], etc.) or laboratory findings, except for conditions associated with CNS lymphoma, which in the investigator's opinion might jeopardize patient's safety or compliance with the protocol.
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioCTIS2024-513938-38-00Immunocore Limited30
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioEUCTR2021-002008-11-ESImmunocore Limited53
招募中
2 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection2024-513938-38-00Immunocore Limited20
进行中（未招募）
1 期
An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000327-27-Outside-EU/EEAIonis Pharmaceuticals, Inc.34
已完成
1 期
A phase I study of SPM-011 and BNCT30 in patients with recurrent malignant gliomaJPRN-jRCT2051210053Miyatake Shin-ichi9